ABBVIE INC. news, videos and press releases
For more news please use our advanced search feature.
ABBVIE INC. - More news...
ABBVIE INC. - More news...
- Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
- Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
- AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
- AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
- AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics
- AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
- AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
- AbbVie Completes Acquisition of Aliada Therapeutics
- Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
- AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
- AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
- AbbVie to Present at Citi's 2024 Global Healthcare Conference
- Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
- Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
- AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
- AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
- AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
- Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
- AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
- AbbVie Reports Third-Quarter 2024 Financial Results
- AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
- AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
- BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
- U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
- Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
- AbbVie to Host Third-Quarter 2024 Earnings Conference Call
- AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
- AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
